TherapeuticsMD, Inc. (TXMD)
USD 1.42
(2.16%)
USD 1.42
(2.16%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -8.4 Million USD | -139.39% |
| 2022 | 11.85 Million USD | 115.75% |
| 2021 | -78.56 Million USD | 10.25% |
| 2020 | -149.47 Million USD | -2.42% |
| 2019 | -156.3 Million USD | -15.41% |
| 2018 | -127.64 Million USD | -64.88% |
| 2017 | -76.71 Million USD | 13.74% |
| 2016 | -89.74 Million USD | -5.42% |
| 2015 | -85.12 Million USD | -57.92% |
| 2014 | -53.98 Million USD | -109.82% |
| 2013 | -25.68 Million USD | -59.23% |
| 2012 | -26.39 Million USD | -198.2% |
| 2011 | -12.79 Million USD | -1230.76% |
| 2010 | -384.43 Thousand USD | 74.09% |
| 2009 | -1.56 Million USD | -296.78% |
| 2008 | -395.55 Thousand USD | -321.95% |
| 2007 | -51 Thousand USD | -121.5% |
| 2006 | -80.81 Thousand USD | 10.96% |
| 2005 | 437.73 Thousand USD | 59.47% |
| 2004 | 238.75 Thousand USD | -11.32% |
| 2003 | 208.46 Thousand USD | 109.1% |
| 2002 | 131.88 Thousand USD | -3.34% |
| 2001 | 137.44 Thousand USD | -24.11% |
| 2000 | 200.32 Thousand USD | 193.34% |
| 1999 | 61.49 Thousand USD | 63.23% |
| 1998 | 37.82 Thousand USD | -46.24% |
| 1997 | 70.37 Thousand USD | -26.1% |
| 1996 | 95.22 Thousand USD | 55.95% |
| 1995 | 66.34 Thousand USD | -10.63% |
| 1994 | 66.66 Thousand USD | 8.43% |
| 1993 | 63.65 Thousand USD | 0.0% |
| 1992 | - USD | 0.0% |
| 1991 | - USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1 Million USD | 21.58% |
| 2024 Q2 | -999 Thousand USD | -27.96% |
| 2023 Q2 | -2.24 Million USD | -0.31% |
| 2023 Q3 | -1.28 Million USD | 42.68% |
| 2023 Q4 | -974 Thousand USD | 24.14% |
| 2023 Q1 | -2.23 Million USD | -102.04% |
| 2023 FY | - USD | -135.64% |
| 2022 FY | - USD | 115.75% |
| 2022 Q4 | 109.59 Million USD | 523.73% |
| 2022 Q3 | -25.86 Million USD | -0.5% |
| 2022 Q1 | -34.17 Million USD | 3.41% |
| 2022 Q2 | -25.73 Million USD | 24.7% |
| 2021 Q3 | -40.34 Million USD | -18.62% |
| 2021 Q2 | -34.01 Million USD | -20.89% |
| 2021 Q1 | -28.13 Million USD | 15.88% |
| 2021 Q4 | -35.38 Million USD | 12.31% |
| 2021 FY | - USD | 10.25% |
| 2020 FY | - USD | -2.42% |
| 2020 Q1 | -49.57 Million USD | -15.95% |
| 2020 Q2 | -44.69 Million USD | 9.85% |
| 2020 Q3 | -23.91 Million USD | 46.5% |
| 2020 Q4 | -33.44 Million USD | -39.89% |
| 2019 Q1 | -37.3 Million USD | -0.29% |
| 2019 Q3 | -26.2 Million USD | 36.13% |
| 2019 FY | - USD | -15.41% |
| 2019 Q2 | -41.03 Million USD | -9.99% |
| 2019 Q4 | -42.75 Million USD | -63.14% |
| 2018 Q4 | -37.2 Million USD | -11.12% |
| 2018 Q2 | -32.62 Million USD | -32.3% |
| 2018 Q1 | -24.65 Million USD | -14.02% |
| 2018 Q3 | -33.47 Million USD | -2.63% |
| 2018 FY | - USD | -64.88% |
| 2017 Q2 | -19.77 Million USD | 6.87% |
| 2017 FY | - USD | 13.74% |
| 2017 Q4 | -21.62 Million USD | -46.33% |
| 2017 Q3 | -14.77 Million USD | 25.28% |
| 2017 Q1 | -21.23 Million USD | 6.81% |
| 2016 Q1 | -20.95 Million USD | -19.8% |
| 2016 Q2 | -21.18 Million USD | -1.11% |
| 2016 Q3 | -25.08 Million USD | -18.41% |
| 2016 Q4 | -22.78 Million USD | 9.17% |
| 2016 FY | - USD | -5.42% |
| 2015 Q2 | -27.21 Million USD | -30.33% |
| 2015 FY | - USD | -57.92% |
| 2015 Q4 | -17.49 Million USD | 10.1% |
| 2015 Q3 | -19.45 Million USD | 28.5% |
| 2015 Q1 | -20.88 Million USD | -28.18% |
| 2014 FY | - USD | -109.82% |
| 2014 Q2 | -10.88 Million USD | -22.17% |
| 2014 Q3 | -17.81 Million USD | -63.7% |
| 2014 Q1 | -8.91 Million USD | -11.71% |
| 2014 Q4 | -16.29 Million USD | 8.58% |
| 2013 FY | - USD | -59.23% |
| 2013 Q4 | -7.97 Million USD | -10.89% |
| 2013 Q3 | -7.19 Million USD | -28.37% |
| 2013 Q2 | -5.6 Million USD | -13.47% |
| 2013 Q1 | -4.93 Million USD | -16.73% |
| 2012 Q3 | -3.95 Million USD | 21.29% |
| 2012 Q4 | -4.23 Million USD | -6.89% |
| 2012 Q2 | -5.02 Million USD | -75.48% |
| 2012 Q1 | -2.86 Million USD | 45.97% |
| 2012 FY | - USD | -198.2% |
| 2011 Q3 | -62.49 Thousand USD | -6.64% |
| 2011 FY | - USD | -1230.76% |
| 2011 Q1 | -41.73 Thousand USD | 61.44% |
| 2011 Q2 | -58.6 Thousand USD | -40.41% |
| 2011 Q4 | -5.3 Million USD | -8384.88% |
| 2010 Q2 | -75.54 Thousand USD | 73.11% |
| 2010 Q4 | -108.24 Thousand USD | -16.67% |
| 2010 Q3 | -92.77 Thousand USD | -22.81% |
| 2010 Q1 | -280.96 Thousand USD | 51.52% |
| 2010 FY | - USD | 74.09% |
| 2009 Q2 | -14.16 Thousand USD | 51.2% |
| 2009 FY | - USD | -296.78% |
| 2009 Q3 | -462.21 Thousand USD | -3162.18% |
| 2009 Q4 | -579.5 Thousand USD | -25.37% |
| 2009 Q1 | -29.03 Thousand USD | -242.65% |
| 2008 Q1 | -35.12 Thousand USD | 89.94% |
| 2008 FY | - USD | -321.95% |
| 2008 Q3 | -46.5 Thousand USD | 84.78% |
| 2008 Q2 | -305.45 Thousand USD | -769.69% |
| 2008 Q4 | -8473.00 USD | 81.78% |
| 2007 Q3 | 121.21 Thousand USD | 9.67% |
| 2007 FY | - USD | -121.5% |
| 2007 Q4 | -349.08 Thousand USD | -387.99% |
| 2007 Q2 | 110.52 Thousand USD | 16.92% |
| 2007 Q1 | 94.53 Thousand USD | -3.02% |
| 2006 Q1 | 87.77 Thousand USD | -27.3% |
| 2006 Q3 | 130.01 Thousand USD | 17.66% |
| 2006 FY | - USD | 10.96% |
| 2006 Q4 | 97.48 Thousand USD | -25.02% |
| 2006 Q2 | 110.49 Thousand USD | 25.89% |
| 2005 Q1 | 94.5 Thousand USD | 51.53% |
| 2005 Q2 | 27.85 Thousand USD | -70.52% |
| 2005 FY | - USD | 59.47% |
| 2005 Q3 | 161.09 Thousand USD | 478.33% |
| 2005 Q4 | 120.72 Thousand USD | -25.06% |
| 2004 Q4 | 62.36 Thousand USD | -12.44% |
| 2004 Q1 | 96 Thousand USD | -1.19% |
| 2004 Q2 | 33.69 Thousand USD | -64.9% |
| 2004 Q3 | 71.22 Thousand USD | 111.37% |
| 2004 FY | - USD | -11.32% |
| 2003 Q2 | 61.71 Thousand USD | 71.14% |
| 2003 FY | - USD | 109.1% |
| 2003 Q4 | 67.32 Thousand USD | 310.56% |
| 2003 Q3 | 38.94 Thousand USD | -76.12% |
| 2003 Q1 | 32.25 Thousand USD | 3.29% |
| 2002 Q4 | 50.05 Thousand USD | 29.11% |
| 2002 Q1 | 13.79 Thousand USD | 73.95% |
| 2002 Q2 | 30.62 Thousand USD | 1232.44% |
| 2002 FY | - USD | -3.34% |
| 2002 Q3 | 37.41 Thousand USD | 18.55% |
| 2001 Q2 | 42.03 Thousand USD | -14.72% |
| 2001 Q1 | 49.29 Thousand USD | -39.36% |
| 2001 FY | - USD | -24.11% |
| 2001 Q4 | -12.41 Thousand USD | -154.89% |
| 2001 Q3 | 22.61 Thousand USD | -46.2% |
| 2000 Q3 | 47.25 Thousand USD | 85.05% |
| 2000 Q2 | 25.53 Thousand USD | 19.15% |
| 2000 Q1 | 21.43 Thousand USD | 19.86% |
| 2000 FY | - USD | 193.34% |
| 2000 Q4 | 81.28 Thousand USD | 72.04% |
| 1999 Q1 | 2367.00 USD | 0.0% |
| 1999 Q3 | 21.63 Thousand USD | 12.64% |
| 1999 Q2 | 19.21 Thousand USD | 711.58% |
| 1999 FY | - USD | 63.23% |
| 1999 Q4 | 17.87 Thousand USD | -17.37% |
| 1998 FY | - USD | -46.24% |
| 1997 FY | - USD | -26.1% |
| 1996 FY | - USD | 55.95% |
| 1995 FY | - USD | -10.63% |
| 1994 FY | - USD | 8.43% |
| 1993 FY | - USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1991 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -150.1 Million USD | 94.403% |
| Theratechnologies Inc. | -10.31 Million USD | 18.538% |
| Safety Shot Inc | -12.18 Million USD | 31.056% |
| Cosmos Health Inc. | -17.06 Million USD | 50.761% |
| Cronos Group Inc. | -72.14 Million USD | 88.356% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 99.092% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 76.717% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 123.316% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -161.301% |
| ProPhase Labs, Inc. | -14.82 Million USD | 43.34% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -85.657% |
| Dynavax Technologies Corporation | 9.66 Million USD | 186.913% |
| Radius Health, Inc. | 38.31 Million USD | 121.929% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -257.336% |
| Alvotech | -484.86 Million USD | 98.267% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -119.667% |
| Alpha Teknova, Inc. | -25.53 Million USD | 67.105% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 94.711% |
| SCYNEXIS, Inc. | 73.47 Million USD | 111.433% |
| Harrow Health, Inc. | 9.72 Million USD | 186.403% |
| Biofrontera Inc. | -18.45 Million USD | 54.474% |
| DURECT Corporation | -24.68 Million USD | 65.966% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 108.55% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 107.685% |
| OptiNose, Inc. | -15.55 Million USD | 45.985% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 131.984% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 810.745% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -1081.825% |
| SIGA Technologies, Inc. | 84.15 Million USD | 109.982% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 1134.606% |
| Shineco, Inc. | -26.55 Million USD | 68.362% |
| Phibro Animal Health Corporation | 84.6 Million USD | 109.929% |
| Procaps Group S.A. | 104.02 Million USD | 108.076% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -132.224% |
| Viatris Inc. | 3.51 Billion USD | 100.239% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -119.667% |
| Rockwell Medical, Inc. | -4.69 Million USD | -78.973% |
| Incannex Healthcare Limited | -18.5 Million USD | 54.599% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -730.138% |
| Tilray Brands, Inc. | -72.84 Million USD | 88.467% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 102.725% |
| PetIQ, Inc. | 81.48 Million USD | 110.31% |
| Silver Spike Investment Corp. | 7.34 Million USD | 214.453% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 102.019% |
| Journey Medical Corporation | 1.92 Million USD | 537.324% |
| Alimera Sciences, Inc. | 7.27 Million USD | 215.462% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -99.46% |
| Assertio Holdings, Inc. | -222.44 Million USD | 96.223% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -110.517% |
| Embecta Corp. | 245.4 Million USD | 103.423% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 58.06% |
| Procaps Group, S.A. | 104.02 Million USD | 108.076% |
| PainReform Ltd. | -9.56 Million USD | 12.206% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 94.366% |
| Hempacco Co., Inc. | -12.77 Million USD | 34.23% |
| Talphera, Inc. | -9.84 Million USD | 14.641% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 105.157% |
| Alvotech | -484.86 Million USD | 98.267% |
| Lantheus Holdings, Inc. | 491 Million USD | 101.711% |
| Kamada Ltd. | 21.53 Million USD | 139.013% |
| Indivior PLC | 66 Million USD | 112.729% |
| Currenc Group, Inc. | -1.9 Million USD | -342.024% |
| Evoke Pharma, Inc. | -7.29 Million USD | -15.204% |
| Flora Growth Corp. | -45.87 Million USD | 81.685% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 58.06% |
| Evolus, Inc. | -41.81 Million USD | 79.907% |
| HUTCHMED (China) Limited | 25.52 Million USD | 132.909% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 103.479% |
| Akanda Corp. | -27.73 Million USD | 69.711% |